Ryosuke Takayasu

Recent publications · Crossref

5 total works indexed

1. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

   · 2018 · cited 5,603x

2. Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

   · 2018 · cited 4,583x

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

   · 2019 · cited 2,788x

4. Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

   · 2020 · cited 2,528x

5. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

   · 2018 · cited 2,386x

via Crossref · CC0